{"type":"trials","record":{"id":41417,"source_id":"clinicaltrials-gov","external_id":"NCT07764965","title":"Evaluation of PAN-90806 Eye Drops in Healthy Subjects","brief_summary":"The goal of this clinical trial is to learn about the safety, tolerability, and systemic pharmacokinetics of PAN-90806 eye drops in healthy adults. It will also evaluate what medical problems participants may have when taking PAN-90806. The main questions it aims to answer are: Is PAN-90806 eye drops safe and well tolerated in healthy participants? What are the systemic pharmacokinetic characteristics of PAN-90806 after ocular administration? What medical problems or adverse events do participants have when taking PAN-90806? Researchers will compare PAN-90806 eye drops to a placebo (a look-alike eye drop that contains no PAN-90806) to evaluate the safety, tolerability, and systemic pharmacokinetics of PAN-90806. Participants will: Receive PAN-90806 eye drops or placebo eye drops once daily in both eyes, one drop per eye, on Day 1 and Days 3 to 7, for a total of 6 dosing days Stay at the study center during the inpatient dosing period and attend scheduled study visits for screening, admission, dosing, and discharge Undergo blood sampling for pharmacokinetic testing, as well as eye examinations, laboratory tests, vital signs assessments, physical examinations, and ECGs","overall_status":"Not Yet Recruiting","phases":["PHASE1"],"study_type":"INTERVENTIONAL","sponsor":"Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.","enrollment":20,"countries":[],"start_date":"2026-09-30","completion_date":"2026-12-30","last_update_date":"2026-08-14","source_url":"https://clinicaltrials.gov/study/NCT07764965","editorial_summary":"A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"18 Years to 50 Years","comparator":"Vehicle Eye Drops, 0mg/mL","organization":"Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.","interventions":["PAN-90806 Ophthalmic Solution","Vehicle Ophthalmic Solution"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Corneal endothelial cell examination (density(cells/mm2) — Day-14~Day -1, and Day 9 (set Day 0 as the day hospitalized)","Corneal endothelial cell examination (coefficient of variation(% of variation in total endothelial cell size )) — Day-1…","Corneal endothelial cell examination(proportion of hexagonal cells(%)) — Day-14~Day -1, and Day 9 (set Day 0 as the day…","Central corneal thickness (μm) — Day-14~Day -1, and Day 9 (set Day 0 as the day hospitalized)","sodium fluorescein staining score of the cornea (NEI scale for the score) — Day-14~Day -1, Day 2, Day 4, Day 6 and Day…","Conjunctival lissamine green staining score of the cornea (NEI scale for the score) — Day-14~Day -1, Day 2, Day 4, Day…","Best corrected visual acuity(National standard logarithmic eye chart of China) — Day-14~Day -1, Day 2, Day 4, Day 6 and…","intraocular pressure measurements(mmHg) — Day-14~Day -1, Day 2, Day 4, Day 6 and Day 9 (set Day 0 as the day hospitaliz…","slit-lamp biomicroscopy — Day-14~Day -1, Day 2, Day 4, Day 6 and Day 9 (set Day 0 as the day hospitalized)","non-dilated retinal photography — Day-14~Day -1, and Day 9 (set Day 0 as the day hospitalized)","The incidence of adverse events — Day 1~Day 9","The severity of adverse events — Day 1~Day 9","blood pressure (using the portable blood pressure monitor, mmHg) — Day-14~Day -1, and Day 9 (set Day 0 as the day hospi…","Pulse (using the portable blood pressure monitor, beats per minute (BPM)) — Day-14~Day -1, and Day 9 (set Day 0 as the…","Body temperature (Body temperature detection using infrared ear thermometer, ℃) — Day-14~Day -1, and Day 9 (set Day 0 a…","physical examination — Day-14~Day -1, and Day 9 (set Day 0 as the day hospitalized)","electrocardiogra (Heart rate, PR interval(ms), QRS time limit(ms), QT/QTc interval(ms)) — Day-14~Day -1, and Day 9 (set…","electrocardiogra (Heart rate) — Day-14~Day -1, and Day 9 (set Day 0 as the day hospitalized)","electrocardiogra (PR interval(ms)) — Day-14~Day -1, and Day 9 (set Day 0 as the day hospitalized)","electrocardiogra (QT/QTc interval(ms)) — Day-14~Day -1, and Day 9 (set Day 0 as the day hospitalized)"],"design_description":"RANDOMIZED · PARALLEL · HEALTH SERVICES RESEARCH · DOUBLE","source_has_results":false},"controlled_terms":["Wet Age Related Macular Degeneration","Neovascular (Wet) Age-Related Macular Degeneration","PAN-90806 Ophthalmic Solution","Vehicle Ophthalmic Solution"],"relevance_confidence":60,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Source terminology contains: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct07764965","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2026-09-30 to 2026-12-30","comparator":"Vehicle Eye Drops, 0mg/mL","confidence":"structured-source","population":"ALL · 18 Years to 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.808Z","intervention":["PAN-90806 Ophthalmic Solution","Vehicle Ophthalmic Solution"],"participants":20,"study_design":"RANDOMIZED · PARALLEL · HEALTH SERVICES RESEARCH · DOUBLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE1","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Corneal endothelial cell examination (density(cells/mm2) — Day-14~Day -1, and Day 9 (set Day 0 as the day hospitalized)","Corneal endothelial cell examination (coefficient of variation(% of variation in total endothelial cell size )) — Day-1…","Corneal endothelial cell examination(proportion of hexagonal cells(%)) — Day-14~Day -1, and Day 9 (set Day 0 as the day…","Central corneal thickness (μm) — Day-14~Day -1, and Day 9 (set Day 0 as the day hospitalized)","sodium fluorescein staining score of the cornea (NEI scale for the score) — Day-14~Day -1, Day 2, Day 4, Day 6 and Day…","Conjunctival lissamine green staining score of the cornea (NEI scale for the score) — Day-14~Day -1, Day 2, Day 4, Day…","Best corrected visual acuity(National standard logarithmic eye chart of China) — Day-14~Day -1, Day 2, Day 4, Day 6 and…","intraocular pressure measurements(mmHg) — Day-14~Day -1, Day 2, Day 4, Day 6 and Day 9 (set Day 0 as the day hospitaliz…","slit-lamp biomicroscopy — Day-14~Day -1, Day 2, Day 4, Day 6 and Day 9 (set Day 0 as the day hospitalized)","non-dilated retinal photography — Day-14~Day -1, and Day 9 (set Day 0 as the day hospitalized)","The incidence of adverse events — Day 1~Day 9","The severity of adverse events — Day 1~Day 9","blood pressure (using the portable blood pressure monitor, mmHg) — Day-14~Day -1, and Day 9 (set Day 0 as the day hospi…","Pulse (using the portable blood pressure monitor, beats per minute (BPM)) — Day-14~Day -1, and Day 9 (set Day 0 as the…","Body temperature (Body temperature detection using infrared ear thermometer, ℃) — Day-14~Day -1, and Day 9 (set Day 0 a…","physical examination — Day-14~Day -1, and Day 9 (set Day 0 as the day hospitalized)","electrocardiogra (Heart rate, PR interval(ms), QRS time limit(ms), QT/QTc interval(ms)) — Day-14~Day -1, and Day 9 (set…","electrocardiogra (Heart rate) — Day-14~Day -1, and Day 9 (set Day 0 as the day hospitalized)","electrocardiogra (PR interval(ms)) — Day-14~Day -1, and Day 9 (set Day 0 as the day hospitalized)","electrocardiogra (QT/QTc interval(ms)) — Day-14~Day -1, and Day 9 (set Day 0 as the day hospitalized)"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Source terminology contains: age-related macular degeneration.","Source terminology supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["controlled terminology","controlled context","study type"],"relevance_score":60,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41417","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}